Predictors of outcomes with CD3 x CD20 bispecific antibodies after CAR-T failure in B-cell lymphoma
3:05
Real-world outcomes of treatment with bispecific T-cell engaging antibodies for R/R LBCL
8:11
MPN Research Spotlight: Highlights from ASH 2024
2:48
Outcomes of CAR T-cell therapy in patients with transformed FL versus de novo DLBCL
16:34
Excess deaths in young adults
16:21
Dramatic neurological improvement after perispinal etanercept treatment by Edward Tobinick, M.D.
2:27
Cevostamab in patients with triple-class refractory MM after prior BCMA-targeted bispecific antibody
11:24
From Auckland to the INR in Boca Raton, Florida August 2014 720p
7:26